BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release BioXcel Therapeutics (BTAI) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…
BioXcel Therapeutics Aktie: Die Verluste bergen Gefahren Die BioXcel Therapeutics Aktie setzt ihren negativen Trend auch im neuen Jahr fort. Am 11. Januar 2025 verzeichnete das Papier…
BioXcel Therapeutics Announces Proposed Public Offering NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical…
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing…
BioXcel Therapeutics Aktie: Kursanstieg trotz herausforderndem Marktumfeld BioXcel Therapeutics verzeichnete am 14. September 2024 einen Kursanstieg von 1,64% auf 0,62 EUR. Dies markiert eine positive Entwicklung für…
BioXcel Therapeutics secures $25 million in direct offering By Investing.com BioXcel Therapeutics secures $25 million in direct offering…
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing…